Liver Cancer Trial, Recruiting NCT06990659 Sponsor: University Hospital, Angers Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06990659
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older.
  • People diagnosed with hepatocellular carcinoma (a type of liver cancer) or intrahepatic cholangiocarcinoma (a type of bile duct cancer), confirmed either through standard liver association guidelines or through a tissue biopsy.
  • People whose cancer has been assessed as suitable for a procedure that delivers treatment directly through the arteries of the liver — either chemoembolization (TACE) or radioembolization (TARE) — and who have not previously had that same type of procedure (confirm with trial site for details on prior treatments).
  • For people being considered for TACE: liver function must meet a certain threshold (Child-Pugh score below B8), the cancer may be a single tumour or multiple tumours, there must be no major blockage of the portal vein, and no widening of the bile ducts.
  • For people being considered for TARE: there must be no tumour invasion of the main portal vein trunk, the tumour must generally be confined to one side of the liver (with an exception for certain centrally located bile duct cancers), and bilirubin levels must be below a certain level (confirm with trial site).
  • People covered by a social security or health insurance scheme.
  • People who have read and signed the trial's informed consent form.

Who may not be able to join:

  • People for whom the procedure would be technically too difficult or not possible based on their anatomy.
  • People for whom a combined same-day treatment is planned alongside the trial procedure (for example, having TACE and a tumour ablation on the same day); treatments carried out on separate days are generally permitted.
  • People with severe chronic kidney disease (kidney filtration rate below 30 ml/min).
  • People with a known allergy to contrast dye or chemotherapy agents used in the procedure.
  • People who would not be able to safely manage outpatient (day procedure) care — for example, those who could not follow discharge instructions, do not have reliable phone access, would not have a responsible adult with them on the first night after discharge, or could not reach urgent medical care quickly if needed.
  • People who have already been enrolled in this trial previously.
  • People who, due to psychological, social, family, or geographical reasons, would not be able to attend regular follow-up appointments.
  • People with a serious uncontrolled medical condition or clinical situation.
  • People with a severe uncontrolled infection.
  • People who are pregnant, breastfeeding, or in labour.
  • People who are currently detained or imprisoned by a court or administrative order.
  • People who are under compulsory psychiatric treatment.
  • People who are under a legal protection or guardianship order.
  • People who are not able to give informed consent.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christophe AUBE, Pr, University Hospital, Angers

Phone: +33(0)24-135-4281

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Angers
Registry
ClinicalTrials.gov
Start date
18 December 2025
Est. completion
17 December 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Overall patient satisfaction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov